Clarivate (CLVT) Q4 2025 earnings summary

Executive summary

• Achieved and exceeded full-year financial guidance for the first time since 2019, marking a positive inflection point driven by the Value Creation Plan and portfolio optimization.

• Accelerated organic ACV and recurring revenue growth, with improved free cash flow conversion and stable 93% revenue retention.

• Initiated and actively progressed the sale of the Life Sciences & Healthcare (LS&H) segment to focus on A&G and IP markets and strengthen the balance sheet.

• Leveraged proprietary solutions and AI to drive innovation and customer value, with 97% of revenue from proprietary assets.

• Shift toward subscription-based services increased recurring revenue mix to 88%.

Financial highlights

• FY 2025 revenue: $2,455 million, down $102 million year-over-year due to disposals and divestitures; Q4 revenue: $617 million.

• Net loss improved to $(201) million from $(637) million in FY 2024, mainly due to lower impairment and reduced interest/tax expense.

• Adjusted EBITDA for 2025 was $1,002 million (40.8% margin), down from $1,060 million (41.5%) in 2024.

• Adjusted diluted EPS was $0.69, compared to $0.73 in the prior year.

• Free cash flow for 2025 was $365 million, up from $357.5 million in 2024.

Outlook and guidance

• FY 2026 guidance: revenue of $2.30B–$2.42B, organic ACV growth of 2.0%–3.0%, and recurring organic revenue growth of 0.75%–2.25%.

• Adjusted EBITDA projected at $980M–$1.04B (42.0%–43.5% margin); adjusted diluted EPS $0.70–$0.80.

• Free cash flow guidance of $400M–$435M, representing ~10% growth over 2025.

• Revenue expected to decline by ~$100 million due to disposals, but recurring revenue mix to improve to 88%–90%.